 |
|
|
Martin S. Angst
Email:
Profile: http://med.stanford.edu/profiles/Martin_Angst/
Alternate Contact: Academic Appointments
Appointment
Organization
Assistant Professor - Med Center Line (PI Waver)
Associate Professor - Med Center Line
|
Curriculum Vitae PDF
Research Interests
Our human experimental pain research laboratory was launched in 1995. Initial research focused on using experimental pain models in phase I/II clinical trails testing for analgesic efficacy and profile of novel analgesic drug candidates (systemic a2-adrenergic agonists) and of established analgesic drugs delivered with aid of innovative technology (opioids and oral osmotic pump systems). A second early interest examined the mode and site of action after intrathecal or epidural administration of analgesic drugs (spinal versus supraspinal effects).
Today, our laboratory is active in three major research areas. With aid of various pain models mimicking acute pain, inflammatory pain, and pain due to amplified neuronal processing at the level of the spinal cord we study plastic changes within the central nervous system as a consequence of analgesic drug therapy (opioid induced pain hypersensitivity), develop a biomarker assay in humans (cytokines, growth factors, neuropeptides, prostaglandins) for early validation or rejection of novel anti-inflammatory and analgesic drug candidates, and search for genetic differences (single nucleotide polymorphisms) responsible for inter-individual variations in pain sensitivity and responsiveness to analgesic drugs. Besides the experimental pain models we use techniques such as micro-dialysis, laser-doppler imaging, and immunohistochemistry to find answers to our questions.
Today, our laboratory is active in three major research areas. With aid of various pain models mimicking acute pain, inflammatory pain, and pain due to amplified neuronal processing at the level of the spinal cord we study plastic changes within the central nervous system as a consequence of analgesic drug therapy (opioid induced pain hypersensitivity), develop a biomarker assay in humans (cytokines, growth factors, neuropeptides, prostaglandins) for early validation or rejection of novel anti-inflammatory and analgesic drug candidates, and search for genetic differences (single nucleotide polymorphisms) responsible for inter-individual variations in pain sensitivity and responsiveness to analgesic drugs. Besides the experimental pain models we use techniques such as micro-dialysis, laser-doppler imaging, and immunohistochemistry to find answers to our questions.
Publications
- Chu LF, Angst MS, Clark D "Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations." Clin J Pain 2008 Jul-Aug; 24: 6: 479-96 More »
- Liang DY, Shi X, Qiao Y, Angst MS, Yeomans DC, Clark JD "Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision." Mol Pain 2008; 4: 1: 7 More »
- Angst MS, Clark JD, Carvalho B, Tingle M, Schmelz M, Yeomans DC "Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: A microdialysis study." Pain 2008; More »
- Carvalho B, Clark DJ, Angst MS "Local and Systemic Release of Cytokines, Nerve Growth Factor, Prostaglandin E2, and Substance P in Incisional Wounds and Serum Following Cesarean Delivery." J Pain 2008; More »
- Angst MS, Clark JD "Comment on Koltzenburg et al.: Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;126:165-174." Pain 2007; More »
39 publications: view full list
